"But isn't exercise dangerous for me?"
That question comes up again and again in muscle disease clinics.
People with myotonic dystrophy (myotonic dystrophy = inherited muscle disease with slow-relaxing muscles) often hear conflicting advice. Some are told to rest. Others are pushed to train. No one is quite sure what's safe.
Meanwhile, the disease itself keeps chipping away at strength, endurance, and daily energy.
Myotonic dystrophy type 1, or DM1, is one of the most common adult-onset muscular diseases.
It runs in families. It causes muscle weakness, stiff muscles that are slow to relax, fatigue, and often sleep and heart issues. There is no medicine that stops the underlying process.
That leaves daily life quality as the main target of care — and exercise is one of the oldest, cheapest tools in medicine. The question has been whether it helps, hurts, or does nothing in DM1.
The old worry, and what changed
For a long time, families and even some clinicians worried that exercise might damage already-fragile muscles.
But here's the twist. Over the past two decades, small studies began showing that carefully prescribed training was usually well tolerated. Researchers wanted to know: do the benefits hold up when you pool the evidence?
This new systematic review and meta-analysis does exactly that.
How it works, in plain terms
Think of muscle like a rechargeable battery.
In DM1, the battery charges more slowly and drains faster. The concern was that demanding workouts might "overuse" a damaged battery.
What the data actually suggest is more hopeful. With the right program — not too hard, not too easy — the battery can hold a little more charge, even with the disease.
The authors searched six research databases for studies published between 2003 and 2023.
They included randomized controlled trials, quasi-experimental studies, and longitudinal cohort studies. Adults with DM1 had to be doing aerobic training (like cycling or walking), resistance training (weights), or both.
Fourteen studies met the bar. Most had a low risk of bias, meaning their methods were reasonably trustworthy.
The headline finding: exercise was safe.
Only one study reported any adverse events, and those events happened at similar rates in the exercise groups and the "usual care" groups. In other words, training did not appear to add harm.
The meta-analysis showed a moderate improvement in muscle strength, and that improvement was statistically meaningful.
Endurance (how long people could keep going) showed a larger-looking benefit on average, but the result didn't cross the line into statistical significance. That's often a sign that more or bigger studies are needed.
Exercise did not "cure" DM1 — and the authors do not claim it did.
Fatigue and sleep outcomes were mixed. Some studies showed small gains, others showed no change.
Here's where it gets interesting
The safety finding may be the most practical result for families.
Many adults with DM1 have avoided gyms, physical therapy, or even daily walks out of fear. This review offers a measured green light: under guidance, training appears to be a reasonable thing to try.
Muscle-disease specialists have been cautiously pro-exercise for several years. This review adds weight to that position.
It also fits a wider pattern in neuromuscular care: moving from "rest and protect" toward "gentle, consistent loading." The goal is preserving function, not winning marathons.
If you live with DM1 and are curious about exercise, please don't design a program alone.
Talk to your neurologist or a physical therapist with experience in neuromuscular disease. They can screen your heart, set safe starting levels, and match the program to your current strength and endurance.
Aerobic training — like a stationary bike at moderate effort — plus light resistance work tends to be a reasonable starting point in the research. Start low. Go slow. Expect weeks, not days, before noticeable change.
Fourteen studies is a modest evidence base.
The trials used different exercise types, different durations, and different outcome tools. That makes it hard to say exactly which program works best.
Most studies were short. Long-term effects on disease progression are still unclear. And because DM1 affects the heart, careful medical screening before exercise remains essential.
The authors call for well-powered trials with standardized exercise protocols. That would answer practical questions like how many sessions per week, what intensity, and for how long.
Until then, the message is cautiously encouraging. Structured exercise appears safe for most adults with DM1 and offers modest, real gains in strength.
